Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2020 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Provides Update on Opaganib (Yeliva®)

Phase 2 study evaluating RedHill’s proprietary NCE1 opaganib (Yeliva®, ABC294640) in prostate cancer initiated at Medical University of South Carolina, supported by an NCI grant --- ...
September 06, 2018 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA® for Cholangiocarcinoma

The first stage of the Phase IIa study with YELIVA® for advanced cholangiocarcinoma (bile duct cancer), a highly lethal malignancy, achieved its pre-specified efficacy goal, and the study can...
March 10, 2016 09:02 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential of YELIVA™ in Cholangiocarcinoma Cancer

The article was authored by scientists from the Mayo Clinic Cancer Center, the Hollings Cancer Center at the Medical University of South Carolina and Apogee Biotechnology Corporation RedHill...